Abbvie Inc (ABBV)

$232.36 +0.07 (0.03%)
Market Cap 410.55B
Revenue (ttm) 56.33B
Net Income (ttm) 4.28B
EPS (ttm) N/A
PE Ratio 24.68
Forward PE 21.91
Profit Margin 7.59%
Debt to Equity Ratio -26.45
Volume 5,461,500
Avg Vol 5,990,028
Day's Range N/A - N/A
Shares Out 1.77B
Stochastic %K 74%
Beta 0.50
Analysts Strong Sell
Price Target $244.08

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 847 932 7900
Address:
1 North Waukegan Road, North Chicago, United States
WayneSmith
WayneSmith Nov. 15 at 10:48 PM
$COST $HD $ABBV $BAC The market is nowshrouded in bullish sentiment.
0 · Reply
HedgeAlerts
HedgeAlerts Nov. 15 at 10:16 PM
Hedge Alert Live - Protect Your Portfolio Contract: $ABBV $230.00 Put · NOV 21, 2025 Exp Entry Price: $1.96 - $2.19 Exit Price Target: $4.39 Profit Margin: +124% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 15 at 9:56 PM
$ABBV: The current market context shows a last close at $232.36, with an RSI of 54.77 indicating neutral momentum, suggesting potential for upward movement without being overbought. The 30-day moving average (MA30) at $226.58 and the 50-day moving average (MA50) at $224.82 are both below the last close, indicating a bullish trend in the short term. The 60-day high of $244.81 presents a potential resistance level, while the low of $205.49 establishes a support range. Directional bias leans bullish due to the price being above both MAs and the RSI indicating room for growth. Suggested entry: $233.00. Stop loss: $228.00 (below the MA30). Targets: $240.00 (first target) and $244.00 (second target, near the 60D high). Monitor for volatility with an ATR of 5.79, adjusting stop levels as necessary. https://privateprofiteers.com
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Nov. 15 at 1:21 PM
💎 LiquidTheta® Live Actionable Trade Asset: $ABBV Contracts: $ABBV December 18, 2026 $240 Calls Scale in: $21.02- $25.69 Scale out: $81.73-$140.10 Profit Potential : 263% ROI Blended Join 💎 Here: https://liquidtheta.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 15 at 7:53 AM
$ABBV: The current market context shows a last close at $232.36, with an RSI of 54.77 indicating neutral momentum, suggesting potential for upward movement without being overbought. The 30-day moving average (MA30) at $226.58 and the 50-day moving average (MA50) at $224.82 are both below the last close, indicating a bullish trend in the short term. The 60-day high of $244.81 presents a potential resistance level, while the low of $205.49 establishes a support range. Directional bias leans bullish due to the price being above both MAs and the RSI indicating room for growth. Suggested entry: $233.00. Stop loss: $228.00 (below the MA30). Targets: $240.00 (first target) and $244.00 (second target, near the 60D high). Monitor for volatility with an ATR of 5.79, adjusting stop levels as necessary. https://privateprofiteers.com
0 · Reply
Ashte
Ashte Nov. 14 at 11:39 PM
$XLV not a good day today, but on weekly still in uptrend … $LLY $ABBV leaders so far
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 14 at 11:14 PM
$ABBV: The last close at $232.36 indicates a position above both the 30-day MA of $226.58 and the 50-day MA of $224.82, suggesting a bullish trend. The RSI at 54.77 indicates that the stock is neither overbought nor oversold, providing room for upward movement. The 60-day high of $244.81 presents a potential resistance level, while the 60-day low of $205.49 serves as a strong support base. Directional bias is bullish due to the price being above key moving averages and the RSI indicating strength without being overextended. Suggested entry: $233.00 (slightly above last close to confirm momentum). Stop loss: $226.00 (below the 30-day MA for protection). Targets: $240.00 (near the 60D high) and $245.00 (psychological level). Monitor for any changes in market conditions or volatility that may affect these levels. https://privateprofiteers.com
0 · Reply
biolover
biolover Nov. 14 at 7:04 PM
$ABBV $VKTX CEO probably wants but CFO getting little stingy. Abbv likely got spoiled with little payment deal with GUBRA. Also made blunder on last two $10 B deals (. One IMGN. Disclosure I had big position in it then But Abbv over paid, and Cerevel where they ended up dumping drug ) But Abbv is big on cash payment drugs and may enter bidding war sooner or later. They view obesity their growth engine into 2040s
0 · Reply
BlondeAmbition
BlondeAmbition Nov. 14 at 6:49 PM
$ABBV $VKTX Partner with Viking…Dumbass😡🤯
0 · Reply
HedgeAlerts
HedgeAlerts Nov. 14 at 5:58 PM
Hedge Alert Live - Protect Your Portfolio Contract: $ABBV $232.50 Put · NOV 21, 2025 Exp Entry Price: $2.93 - $3.10 Exit Price Target: $5.42 Profit Margin: +85% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
Latest News on ABBV
AbbVie Inc. (ABBV) Presents at 7th Annual Healthcare Symposium Transcript

Nov 14, 2025, 4:31 PM EST - 1 day ago

AbbVie Inc. (ABBV) Presents at 7th Annual Healthcare Symposium Transcript

Biopharma companies have confidence in their ability to do deals: BMO's Evan Seigerman

Nov 14, 2025, 3:19 PM EST - 1 day ago

Biopharma companies have confidence in their ability to do deals: BMO's Evan Seigerman

AZN JNJ LLY MRK NVO PFE XLV

AbbVie Announces 20 Recipients of Migraine Career Catalyst Award™

Nov 13, 2025, 8:30 AM EST - 2 days ago

AbbVie Announces 20 Recipients of Migraine Career Catalyst Award™

AbbVie Shares Rise To Intraday High After Key Trading Signal

Nov 12, 2025, 3:06 PM EST - 3 days ago

AbbVie Shares Rise To Intraday High After Key Trading Signal

Chiesi Group Enters into an Exclusive License Agreement with Aliada Therapeutics, a Wholly Owned Subsidiary of AbbVie, to Advance Blood-Brain Barrier-Crossing Platform Technology in Lysosomal Storage Disorders

Nov 12, 2025, 8:30 AM EST - 3 days ago

Chiesi Group Enters into an Exclusive License Agreement with Aliada Therapeutics, a Wholly Owned Subsidiary of AbbVie, to Advance Blood-Brain Barrier-Crossing Platform Technology in Lysosomal Storage Disorders

Allergan Aesthetics Unveils New Data at 2025 American Society for Dermatologic Surgery Annual Meeting Showcasing Transformative Innovation and Portfolio Excellence

Nov 12, 2025, 8:30 AM EST - 3 days ago

Allergan Aesthetics Unveils New Data at 2025 American Society for Dermatologic Surgery Annual Meeting Showcasing Transformative Innovation and Portfolio Excellence

AbbVie Has Many Bullish Attributes (Technical Analysis)

Nov 11, 2025, 10:40 PM EST - 3 days ago

AbbVie Has Many Bullish Attributes (Technical Analysis)

Healthcare Q3 Dividend Roundup: I Prefer AbbVie Over Pfizer

Nov 8, 2025, 6:38 AM EST - 7 days ago

Healthcare Q3 Dividend Roundup: I Prefer AbbVie Over Pfizer

PFE

Biotech is back. Here's why these rallying stocks belong in your portfolio now.

Nov 3, 2025, 9:58 AM EST - 12 days ago

Biotech is back. Here's why these rallying stocks belong in your portfolio now.

ALNY AMGN BMY LLY MBX MDGL MEDI

ADP, Snap-on Lead 14 Companies To Announce Annual Increases In First Half Of November

Nov 1, 2025, 11:15 PM EDT - 13 days ago

ADP, Snap-on Lead 14 Companies To Announce Annual Increases In First Half Of November

ADP AEP AIZ AOS ATO BDX BRO

Best Dividend Aristocrats For November 2025

Nov 1, 2025, 10:25 AM EDT - 14 days ago

Best Dividend Aristocrats For November 2025

ABT ADM ADP AMCR AOS ATO BDX

AbbVie Inc. (ABBV) Q3 2025 Earnings Call Transcript

Oct 31, 2025, 3:56 PM EDT - 15 days ago

AbbVie Inc. (ABBV) Q3 2025 Earnings Call Transcript

AbbVie Raises 2025 Outlook Helped By Strong Immunology Growth, Boost Dividend

Oct 31, 2025, 11:47 AM EDT - 15 days ago

AbbVie Raises 2025 Outlook Helped By Strong Immunology Growth, Boost Dividend

AbbVie: Why Q3 Confirms Its Immunology Dominance

Oct 31, 2025, 10:39 AM EDT - 15 days ago

AbbVie: Why Q3 Confirms Its Immunology Dominance

AbbVie Lifts Profit Outlook as Sales Rise

Oct 31, 2025, 8:42 AM EDT - 15 days ago

AbbVie Lifts Profit Outlook as Sales Rise

AbbVie Beats Third-Quarter Estimates. There's More to the Drugmaker's Earnings.

Oct 31, 2025, 8:20 AM EDT - 15 days ago

AbbVie Beats Third-Quarter Estimates. There's More to the Drugmaker's Earnings.

AbbVie lifts annual profit forecast on resilient demand for newer immunology drugs

Oct 31, 2025, 7:54 AM EDT - 15 days ago

AbbVie lifts annual profit forecast on resilient demand for newer immunology drugs

AbbVie Reports Third-Quarter 2025 Financial Results

Oct 31, 2025, 7:49 AM EDT - 15 days ago

AbbVie Reports Third-Quarter 2025 Financial Results

The One & Only BOTOX® Cosmetic (onabotulinumtoxinA) Day Returns November 19 with the Biggest Celebration of the Year

Oct 29, 2025, 5:00 PM EDT - 17 days ago

The One & Only BOTOX® Cosmetic (onabotulinumtoxinA) Day Returns November 19 with the Biggest Celebration of the Year

AbbVie Announces Positive Topline Results from Phase 3 Pivotal Studies Evaluating Upadacitinib (RINVOQ®) in Adults and Adolescents with Vitiligo

Oct 29, 2025, 8:11 AM EDT - 17 days ago

AbbVie Announces Positive Topline Results from Phase 3 Pivotal Studies Evaluating Upadacitinib (RINVOQ®) in Adults and Adolescents with Vitiligo

Best Dividend Kings: October 2025

Oct 29, 2025, 5:11 AM EDT - 17 days ago

Best Dividend Kings: October 2025

ABM ABT ADM ADP AWR BDX BKH

AbbVie: Deep Discount Before Earnings

Oct 28, 2025, 11:28 AM EDT - 18 days ago

AbbVie: Deep Discount Before Earnings

Healthy Returns: What to expect from Eli Lilly, Merck, Gilead and AbbVie third-quarter earnings

Oct 28, 2025, 10:40 AM EDT - 18 days ago

Healthy Returns: What to expect from Eli Lilly, Merck, Gilead and AbbVie third-quarter earnings

GILD LLY MRK

Final Trades: Abbvie, Qualcomm, Aptiv, and Palo Alto Networks

Oct 21, 2025, 2:27 PM EDT - 25 days ago

Final Trades: Abbvie, Qualcomm, Aptiv, and Palo Alto Networks

APTV PANW QCOM

The Confidence Project by BOTOX® Cosmetic (onabotulinumtoxinA) Unveils This Year's Grant Recipients

Oct 21, 2025, 8:00 AM EDT - 25 days ago

The Confidence Project by BOTOX® Cosmetic (onabotulinumtoxinA) Unveils This Year's Grant Recipients

AbbVie's Rinvoq shows superiority over Humira in head-to-head study

Oct 20, 2025, 8:12 AM EDT - 26 days ago

AbbVie's Rinvoq shows superiority over Humira in head-to-head study

RINVOQ® (upadacitinib) Demonstrated Superiority Versus HUMIRA® (adalimumab) for Primary Endpoint in a Head-to-Head Study in Rheumatoid Arthritis Patients Who Have Failed First TNF Inhibitor

Oct 20, 2025, 8:00 AM EDT - 26 days ago

RINVOQ® (upadacitinib) Demonstrated Superiority Versus HUMIRA® (adalimumab) for Primary Endpoint in a Head-to-Head Study in Rheumatoid Arthritis Patients Who Have Failed First TNF Inhibitor

AbbVie: "Strong Buy" On Rinvoq Expansions And Immunology Pipeline Addition

Oct 17, 2025, 4:34 PM EDT - 4 weeks ago

AbbVie: "Strong Buy" On Rinvoq Expansions And Immunology Pipeline Addition

AbbVie Completes Acquisition of Gilgamesh Pharmaceuticals' Bretisilocin

Oct 17, 2025, 9:00 AM EDT - 4 weeks ago

AbbVie Completes Acquisition of Gilgamesh Pharmaceuticals' Bretisilocin

Final Trades: Abbvie, Amazon, Datadog and Sixth Street Specialty Lending

Oct 13, 2025, 1:28 PM EDT - 4 weeks ago

Final Trades: Abbvie, Amazon, Datadog and Sixth Street Specialty Lending

AMZN DDOG TSLX

U.S. Food and Drug Administration (FDA) Approves Updated Indication Statement for RINVOQ® (upadacitinib) for the Treatment of Inflammatory Bowel Disease

Oct 13, 2025, 10:57 AM EDT - 4 weeks ago

U.S. Food and Drug Administration (FDA) Approves Updated Indication Statement for RINVOQ® (upadacitinib) for the Treatment of Inflammatory Bowel Disease

AbbVie to Present New Data at ESMO 2025 Reinforcing Leadership in Advancing Targeted Therapies for Solid Tumors

Oct 13, 2025, 7:15 AM EDT - 4 weeks ago

AbbVie to Present New Data at ESMO 2025 Reinforcing Leadership in Advancing Targeted Therapies for Solid Tumors

SkinMedica® Debuts Reimagined Packaging and Unveils New HA5® Hydra Collagen Water Burst Moisturizer

Oct 9, 2025, 8:00 AM EDT - 5 weeks ago

SkinMedica® Debuts Reimagined Packaging and Unveils New HA5® Hydra Collagen Water Burst Moisturizer

My Top 5 Biotech Stocks Big Pharma Could Buy Next

Oct 6, 2025, 1:29 PM EDT - 5 weeks ago

My Top 5 Biotech Stocks Big Pharma Could Buy Next

ALVO AMGN ARKG AZN BIIB BMY GILD

AbbVie Announces Positive Topline Results from Phase 2 ELATE Trial Evaluating OnabotulinumtoxinA (BOTOX®) for the Treatment of Upper Limb Essential Tremor

Oct 6, 2025, 9:00 AM EDT - 5 weeks ago

AbbVie Announces Positive Topline Results from Phase 2 ELATE Trial Evaluating OnabotulinumtoxinA (BOTOX®) for the Treatment of Upper Limb Essential Tremor

AbbVie expects $2.7 billion R&D charge in third quarter

Oct 3, 2025, 4:16 PM EDT - 6 weeks ago

AbbVie expects $2.7 billion R&D charge in third quarter

AbbVie: Wins Accumulating While We Wait For Next BD Steps

Oct 3, 2025, 11:05 AM EDT - 6 weeks ago

AbbVie: Wins Accumulating While We Wait For Next BD Steps

ABBV Stock vs. Eli Lilly & Merck

Oct 2, 2025, 8:20 AM EDT - 6 weeks ago

ABBV Stock vs. Eli Lilly & Merck

LLY MRK

AbbVie to Host Third-Quarter 2025 Earnings Conference Call

Oct 2, 2025, 8:00 AM EDT - 6 weeks ago

AbbVie to Host Third-Quarter 2025 Earnings Conference Call

Natrelle® Awarded Supplier Agreement from Vizient

Oct 1, 2025, 8:00 AM EDT - 6 weeks ago

Natrelle® Awarded Supplier Agreement from Vizient

AbbVie Begins Construction on $70 Million Expansion to Further Increase Biologics Manufacturing and R&D Presence in the U.S.

Sep 30, 2025, 3:00 PM EDT - 6 weeks ago

AbbVie Begins Construction on $70 Million Expansion to Further Increase Biologics Manufacturing and R&D Presence in the U.S.

AbbVie Submits Biologics License Application (BLA) to U.S. FDA for Pivekimab sunirine (PVEK) - an Investigational Antibody-Drug Conjugate (ADC) to Treat Rare Cancer with Limited Treatment Options

Sep 30, 2025, 8:00 AM EDT - 6 weeks ago

AbbVie Submits Biologics License Application (BLA) to U.S. FDA for Pivekimab sunirine (PVEK) - an Investigational Antibody-Drug Conjugate (ADC) to Treat Rare Cancer with Limited Treatment Options

Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases

Sep 29, 2025, 7:30 PM EDT - 6 weeks ago

Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases

AbbVie Breaks Ground on New North Chicago Active Pharmaceutical Ingredient Manufacturing Facility

Sep 29, 2025, 12:00 PM EDT - 6 weeks ago

AbbVie Breaks Ground on New North Chicago Active Pharmaceutical Ingredient Manufacturing Facility

AbbVie to launch ovarian cancer drug in UK at the same list price as US

Sep 29, 2025, 9:11 AM EDT - 6 weeks ago

AbbVie to launch ovarian cancer drug in UK at the same list price as US

AbbVie Announces UK Pricing Strategy for ELAHERE® (mirvetuximab soravtansine-gynx)

Sep 29, 2025, 9:00 AM EDT - 6 weeks ago

AbbVie Announces UK Pricing Strategy for ELAHERE® (mirvetuximab soravtansine-gynx)

AbbVie For Healthy Dividend Growth

Sep 27, 2025, 7:00 AM EDT - 7 weeks ago

AbbVie For Healthy Dividend Growth

Many pharma companies already made U.S. investment promises, says Citi's Geoff Meacham

Sep 26, 2025, 4:50 PM EDT - 7 weeks ago

Many pharma companies already made U.S. investment promises, says Citi's Geoff Meacham

AMGN LLY MRK

Pharma tariffs still have a lot of questions outstanding, says Bernstein's Courtney Breen

Sep 26, 2025, 1:47 PM EDT - 7 weeks ago

Pharma tariffs still have a lot of questions outstanding, says Bernstein's Courtney Breen

AMGN GILD LLY MRK MRNA PFE

Portal Innovations' John Flavin: Tariffs on pharma could raise costs and delay drug access

Sep 26, 2025, 12:21 PM EDT - 7 weeks ago

Portal Innovations' John Flavin: Tariffs on pharma could raise costs and delay drug access

LLY MRK PFE BIIB BMY

WayneSmith
WayneSmith Nov. 15 at 10:48 PM
$COST $HD $ABBV $BAC The market is nowshrouded in bullish sentiment.
0 · Reply
HedgeAlerts
HedgeAlerts Nov. 15 at 10:16 PM
Hedge Alert Live - Protect Your Portfolio Contract: $ABBV $230.00 Put · NOV 21, 2025 Exp Entry Price: $1.96 - $2.19 Exit Price Target: $4.39 Profit Margin: +124% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 15 at 9:56 PM
$ABBV: The current market context shows a last close at $232.36, with an RSI of 54.77 indicating neutral momentum, suggesting potential for upward movement without being overbought. The 30-day moving average (MA30) at $226.58 and the 50-day moving average (MA50) at $224.82 are both below the last close, indicating a bullish trend in the short term. The 60-day high of $244.81 presents a potential resistance level, while the low of $205.49 establishes a support range. Directional bias leans bullish due to the price being above both MAs and the RSI indicating room for growth. Suggested entry: $233.00. Stop loss: $228.00 (below the MA30). Targets: $240.00 (first target) and $244.00 (second target, near the 60D high). Monitor for volatility with an ATR of 5.79, adjusting stop levels as necessary. https://privateprofiteers.com
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Nov. 15 at 1:21 PM
💎 LiquidTheta® Live Actionable Trade Asset: $ABBV Contracts: $ABBV December 18, 2026 $240 Calls Scale in: $21.02- $25.69 Scale out: $81.73-$140.10 Profit Potential : 263% ROI Blended Join 💎 Here: https://liquidtheta.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 15 at 7:53 AM
$ABBV: The current market context shows a last close at $232.36, with an RSI of 54.77 indicating neutral momentum, suggesting potential for upward movement without being overbought. The 30-day moving average (MA30) at $226.58 and the 50-day moving average (MA50) at $224.82 are both below the last close, indicating a bullish trend in the short term. The 60-day high of $244.81 presents a potential resistance level, while the low of $205.49 establishes a support range. Directional bias leans bullish due to the price being above both MAs and the RSI indicating room for growth. Suggested entry: $233.00. Stop loss: $228.00 (below the MA30). Targets: $240.00 (first target) and $244.00 (second target, near the 60D high). Monitor for volatility with an ATR of 5.79, adjusting stop levels as necessary. https://privateprofiteers.com
0 · Reply
Ashte
Ashte Nov. 14 at 11:39 PM
$XLV not a good day today, but on weekly still in uptrend … $LLY $ABBV leaders so far
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 14 at 11:14 PM
$ABBV: The last close at $232.36 indicates a position above both the 30-day MA of $226.58 and the 50-day MA of $224.82, suggesting a bullish trend. The RSI at 54.77 indicates that the stock is neither overbought nor oversold, providing room for upward movement. The 60-day high of $244.81 presents a potential resistance level, while the 60-day low of $205.49 serves as a strong support base. Directional bias is bullish due to the price being above key moving averages and the RSI indicating strength without being overextended. Suggested entry: $233.00 (slightly above last close to confirm momentum). Stop loss: $226.00 (below the 30-day MA for protection). Targets: $240.00 (near the 60D high) and $245.00 (psychological level). Monitor for any changes in market conditions or volatility that may affect these levels. https://privateprofiteers.com
0 · Reply
biolover
biolover Nov. 14 at 7:04 PM
$ABBV $VKTX CEO probably wants but CFO getting little stingy. Abbv likely got spoiled with little payment deal with GUBRA. Also made blunder on last two $10 B deals (. One IMGN. Disclosure I had big position in it then But Abbv over paid, and Cerevel where they ended up dumping drug ) But Abbv is big on cash payment drugs and may enter bidding war sooner or later. They view obesity their growth engine into 2040s
0 · Reply
BlondeAmbition
BlondeAmbition Nov. 14 at 6:49 PM
$ABBV $VKTX Partner with Viking…Dumbass😡🤯
0 · Reply
HedgeAlerts
HedgeAlerts Nov. 14 at 5:58 PM
Hedge Alert Live - Protect Your Portfolio Contract: $ABBV $232.50 Put · NOV 21, 2025 Exp Entry Price: $2.93 - $3.10 Exit Price Target: $5.42 Profit Margin: +85% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
BarkingPuppy
BarkingPuppy Nov. 14 at 3:21 PM
$ELTP $ABBV $LLY $JNJ $MRK Someone is looking to make a deal..........Rumors are everywhere!!!!!!! News next week?????? AbbVie Inc.: Recently submitted a New Drug Application (NDA) for tavapadon, a novel treatment for Parkinson's disease. Specific partners and agreements Glenmark Pharmaceuticals: Elite has a license, manufacturing, and supply agreement with Glenmark to market two of Elite's generic products in the US. Glenmark handles sales and distribution, while Elite receives manufacturing and license fees. TAGI Pharma, Epic Pharma, and Valeant Pharmaceuticals International: Elite has licensed generic and OTC products to these companies. Ascend Laboratories: Elite provides contract manufacturing for this subsidiary of Alkem Laboratories Ltd..
0 · Reply
crtlabz
crtlabz Nov. 14 at 1:41 PM
$ABBV buy at the end of the trading day - always fades big at close, especially on a Friday.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Nov. 14 at 12:49 PM
$ABBV RSI: 54.74, MACD: 0.5047 Vol: 6.36, MA20: 224.86, MA50: 223.52 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Nov. 14 at 12:40 PM
💎 LiquidTheta® Live Actionable Trade Asset: $ABBV Contracts: $ABBV December 18, 2026 $240 Calls Scale in: $21.41- $26.17 Scale out: $83.26-$142.73 Profit Potential : 206% ROI Blended Join 💎 Here: https://liquidtheta.com
0 · Reply
_Verticality
_Verticality Nov. 14 at 9:38 AM
Breaking out!? How much volume do you think it takes to gap ARBB up? ARBB has not even 700K shares float and recent news. Hoping for a 100% run on ARBB $UAA $ABBV $SYM $VERI I
0 · Reply
HedgeAlerts
HedgeAlerts Nov. 14 at 7:18 AM
Hedge Alert Live - Protect Your Portfolio Contract: $ABBV $230.00 Put · NOV 21, 2025 Exp Entry Price: $2.21 - $2.52 Exit Price Target: $3.36 Profit Margin: +52% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 14 at 2:48 AM
$ABBV: The last close at $232.29 indicates a stable position within the recent trading range. The RSI at 54.74 suggests a neutral momentum, indicating that the stock is not overbought or oversold. The MA30 at $226.63 and MA50 at $224.42 are both below the last close, providing support levels and indicating a potential bullish trend. The 60D high of $244.81 presents a resistance level, while the 60D low of $205.49 defines the lower boundary of the range. Directional bias is slightly bullish due to the position above the MAs and the neutral RSI. Suggested entry is at $233.50, just above the last close to confirm upward momentum. Set a stop loss at $226.00, below the MA30 for protection. Target 1 is $240.00, approaching the 60D high, and Target 2 is $244.00, slightly below the 60D high for a conservative exit. https://privateprofiteers.com
0 · Reply
_SquidGains_
_SquidGains_ Nov. 13 at 10:53 PM
$T $APH $ABBV $VIVK 1
0 · Reply
DeadBrokerGone
DeadBrokerGone Nov. 13 at 8:29 PM
$LYB $COKE $ABBV $SCHD $BRK.B my port somehow green today
1 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Nov. 13 at 7:36 PM
$SLS Share Price manipulation, ahead of the GPs Top Line Phase 3 Results, is offering a true Once in a Lifetime Investment Opportunity. $229M Manipulated Market Cap - worth $25B to Big Pharma the Instant the Phase 3 Results are Announced. Up to155 Institutional Funds Now Invested / up from just 39 when the IDMC UNBLINDED ACTUAL PHASE 3 INTERIM MOS AND IR DATA. Also, the Market Cap Increased 310% in Value from $77M to $220M Now -- since the IDMC INTERIM DATA was Unblinded. Also, sitting on $73.4M in CASH vs just $13.8M - when the IDMC .... ... AZA/VEN FAILED 3 Phase 3 AML Trials. -- You know $ABBV / $BMY $RHHBY Know Aza VEN are NOT the Reason We are Seeing Miraculous ALL Pooled MOS data...
1 · Reply
GettnFibbywIT
GettnFibbywIT Nov. 13 at 7:26 PM
$ABBV $XLV
0 · Reply
middleman
middleman Nov. 13 at 6:26 PM
$ABBV bulletproof
0 · Reply